Intensity Therapeutics, Inc. (INTS) stock
INTSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.10−0.18 (-5.49%)
Close on Nov 12, 2026Market cap $10.12MP/E –Yield –
Intensity Therapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Intensity Therapeutics's net income for the twelve months ending Sep 30, 2026 was -$12.04M. For fiscal 2025 it was -$11.61M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.61M | – |
| FY2024 | Dec 31, 2024 | -$16.27M | – |
| FY2023 | Dec 31, 2023 | -$10.54M | – |
| FY2022 | Dec 31, 2022 | -$7.58M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$3.54M | – |
| Q2 FY2026 | Jun 30, 2026 | -$3.01M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.43M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.05M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.67M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.54M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.35M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.18M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.51M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.97M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.60M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.17M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.33M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.70M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.34M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.51M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.77M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.93M | – |
See a number that looks wrong?